Cancer is the leading cause of death worldwide, and its treatment and outcomes have been
dramatically revolutionised by targeted therapies. As the most frequently mutated oncogene …

Lung cancer has traditionally been classified by histology. However, a greater
understanding of disease biology and the identification of oncogenic driver alterations has …

Background Among patients with resected, epidermal growth factor receptor (EGFR)–
mutated, stage IB to IIIA non–small-cell lung cancer (NSCLC), adjuvant osimertinib therapy …

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …

Background Osimertinib is a third-generation epidermal growth factor receptor–tyrosine
kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI–sensitizing and EGFR T790M …

In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors
for lung cancer include tobacco use, family history, radiation exposure, and the presence of …

The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …

Protein kinases regulate nearly all aspects of cell life, and alterations in their expression, or
mutations in their genes, cause cancer and other diseases. Here, we review the remarkable …

Oncogenic RET fusions occur in diverse cancers. Pralsetinib is a potent, selective inhibitor of
RET receptor tyrosine kinase. ARROW (NCT03037385, ongoing) was designed to evaluate …

Details on diagnostic procedures are covered in the Supplementary Material Section 2,
available at https://doi. org/10.1016/j. annonc. 2022.12. 009. See Supplementary Figure S1 …